EQUI-GAMMA: Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Recruiting
CT.gov ID
NCT04859335
Collaborator
(none)
50
1
1
66.4
0.8

Study Details

Study Description

Brief Summary

Vestibular schwannomas are benign lesions of the ponto-cerebellar angle that are potentially dangerous because of their growth in a cramped space and the compressive phenomena they can cause. Stereotactic Gammaknife radiosurgery is a treatment option that can be offered for evolutive schwannomas smaller than 2.5-3 cm in size. It allows tumor stabilisation in 85% of cases with less than 1% facial nerve damage risk.

There are controversial results regarding hearing preservation : percentages vary between 25 and 80% in the literature, depending on the criteria used and the post-treatment delay.

Few studies have investigated changes in vestibular function and the impact on balance of radiosurgery, and their results are variable.

These controversial results lead us to comprehensively assess the vestibular function and balance of these patients using a balance-specific quality of life questionnaire, in addition to objective overall vestibular assessments of vestibular function.

Condition or Disease Intervention/Treatment Phase
  • Radiation: gammaknife radiosurgery
N/A

Detailed Description

Vestibular schwannomas are benign lesions of the ponto-cerebellar angle that are potentially dangerous because of their growth in a cramped space and the compressive phenomena they can cause. Stereotactic Gammaknife radiosurgery is a treatment option that can be offered for evolutive schwannomas smaller than 2.5-3 cm in size. It allows tumor stabilisation in 85% of cases with less than 1% facial nerve damage risk.

There are controversial results regarding hearing preservation : percentages vary between 25 and 80% in the literature, depending on the criteria used and the post-treatment delay.

Few studies have investigated changes in vestibular function and the impact on balance of radiosurgery.Their results are heterogeneous, on one hand, indicating little worsening of symptoms, or even improvement in some studies. On the other hand, a 2017 study reported symptomatic worsening of caloric response deficits in 17.6% of cases. Vestibular function at high frequencies or for otolithic organs (utricle and saccule) has hardly ever been explored.

The largest cohort, reported in "gammaknife radiosurgery for vestibular schwannomas a quality of life evaluation" concerns 353 patients and shows that the overall quality of life of the patients treated is on average comparable to that of the general population but that the vertigo is more frequent in this population, with a more marked impact on the overall quality of life.

These controversial results lead us to comprehensively assess the vestibular function and balance of these patients using a balance-specific quality of life questionnaire, in addition to objective overall vestibular assessments of vestibular function.

Thus, the present study aims to assess the quality of balance of patients treated with Gammaknife radiosurgery for vestibular schwannoma at 1 year and 3 years after treatment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Prospective Study : Long-term Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma EQUI-GAMMA
Actual Study Start Date :
May 21, 2021
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Other: Schwannomas patients needing gammaknife radiosurgery

Patients will undergo balance and hearing questionnaires before and after gammaknife radiosurgery. This is a before/after analysis needing only one arm: the "before" data will serve as control to the "after" data

Radiation: gammaknife radiosurgery
Patients will undergo questionnaires before the gammaknife radiosurgery, then one year and three years after the intervention.

Outcome Measures

Primary Outcome Measures

  1. quality of the perceived balance, assessed by the French version of the Dizziness Handicap Inventory (DHI) [before gamma knife radiosurgery (Baseline)]

    Questionnaire including 25 items with a "yes/no/maybe" answer possibility

  2. quality of the perceived balance, assessed by the French version of the Dizziness Handicap Inventory (DHI) [One year after gamma knife radiosurgery]

    Questionnaire including 25 items with a "yes/no/maybe" answer possibility

  3. quality of the perceived balance, assessed by the French version of the Dizziness Handicap Inventory (DHI) [Three years after gamma knife radiosurgery]

    Questionnaire including 25 items with a "yes/no/maybe" answer possibility

Secondary Outcome Measures

  1. Evolution of hearing [before gamma knife radiosurgery (Baseline)]

    Evaluate the evolution of hearing using data obtained during tonal audiometry (frequency by frequency between 250 Hz and 8 kHz, average hearing loss calculated on the frequencies 0.5, 1, 2, and 4 kHz)

  2. Evolution of hearing [One year after gamma knife radiosurgery]

    Evaluate the evolution of hearing using data obtained during tonal audiometry (frequency by frequency between 250 Hz and 8 kHz, average hearing loss calculated on the frequencies 0.5, 1, 2, and 4 kHz)

  3. Evolution of hearing [Three years after gamma knife radiosurgery]

    Evaluate the evolution of hearing using data obtained during tonal audiometry (frequency by frequency between 250 Hz and 8 kHz, average hearing loss calculated on the frequencies 0.5, 1, 2, and 4 kHz)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Vestibular schwannoma's Patients for whom an indication of gammaknife radiosurgery was determined in a dedicated multidisciplinary consultation meeting, having not received previous treatment for this schwannoma.

  • Patient affiliated to Social Security

  • No opposition to participation

Exclusion Criteria:
  • History of prior treatment for the presented vestibular schwannoma (surgery, fractional radiotherapy)

  • History of otological or otoneurological pathology associated with schwannoma

  • Patient with type 2 neurofibromatosis

  • Patient under legal protection

  • Pregnant or breastfeeding women

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Toulouse Toulouse France

Sponsors and Collaborators

  • University Hospital, Toulouse

Investigators

  • Principal Investigator: Mathieu MARX, MD PhD, University Hospital, Toulouse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT04859335
Other Study ID Numbers:
  • RC31/21/0034
First Posted:
Apr 26, 2021
Last Update Posted:
Jul 13, 2021
Last Verified:
Jul 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Toulouse
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 13, 2021